Skip to main content
About Us
About Arcus
Leadership
Board of Directors
Scientific Advisory Board
Contact Us
Pipeline
Clinical Pipeline
Adenosine Axis
Etrumadenant
AB680
Anti-PD1
Zimberelimab
Anti-TIGIT
Domvanalimab
AB308
HIF-2⍺
AB521
Discovery Pipeline
Clinical Trials
Overview
Prostate Cancer
Colorectal Cancer
Lung Cancer
Pancreatic Cancer
Gastrointestinal Cancer
Multiple Cancer Types
Investigator Sponsored
Expanded Access Program
Editorials
Publications
Careers
Investors & Media
Press Releases
Events & Presentations
Events Calendar
Corporate Presentation
Stock Information
Analyst Coverage
Stock Information
SEC Filings
Corporate Governance
Governance Documents
Management Team
Board of Directors
Committee Composition
Contact Investor Relations
Contact Investor Relations
FAQs
Email Alerts
Press Releases
About Us
About Arcus
Leadership
Board of Directors
Scientific Advisory Board
Contact Us
Pipeline
Clinical Pipeline
Adenosine Axis
Etrumadenant
AB680
Anti-PD1
Zimberelimab
Anti-TIGIT
Domvanalimab
AB308
HIF-2⍺
AB521
Discovery Pipeline
Clinical Trials
Overview
Prostate Cancer
Colorectal Cancer
Lung Cancer
Pancreatic Cancer
Gastrointestinal Cancer
Multiple Cancer Types
Investigator Sponsored
Expanded Access Program
Editorials
Publications
Careers
Investors & Media
Press Releases
Events & Presentations
Events Calendar
Corporate Presentation
Stock Information
Analyst Coverage
Stock Information
SEC Filings
Corporate Governance
Governance Documents
Management Team
Board of Directors
Committee Composition
Contact Investor Relations
Contact Investor Relations
FAQs
Email Alerts
Select Year:
For new employee inducement grant announcement inquiries, please contact the company at
investorinfo@arcusbio.com
.